Aethlon Medical, Inc. (NASDAQ:AEMD) Receives Average Recommendation of “Strong Buy” from Analysts

Shares of Aethlon Medical, Inc. (NASDAQ:AEMD) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports.

Analysts have set a one year consensus price target of $6.25 for the company and are anticipating that the company will post ($0.08) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aethlon Medical an industry rank of 36 out of 256 based on the ratings given to related companies.

Separately, ValuEngine lowered Aethlon Medical from a “buy” rating to a “hold” rating in a report on Thursday, August 1st.

A hedge fund recently bought a new stake in Aethlon Medical stock. Bank of New York Mellon Corp bought a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 30,363 shares of the medical equipment provider’s stock, valued at approximately $50,000. Bank of New York Mellon Corp owned approximately 0.17% of Aethlon Medical as of its most recent SEC filing. Hedge funds and other institutional investors own 4.42% of the company’s stock.

NASDAQ AEMD traded down $0.02 on Friday, hitting $0.26. 11,896 shares of the stock traded hands, compared to its average volume of 180,587. The stock’s fifty day simple moving average is $0.32. Aethlon Medical has a 12 month low of $0.20 and a 12 month high of $1.74. The company has a market cap of $4.49 million, a price-to-earnings ratio of -0.76 and a beta of 1.20.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Monday, July 1st. The medical equipment provider reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.08 million. On average, equities analysts forecast that Aethlon Medical will post -0.27 earnings per share for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals.

Read More: What are popular green investing opportunities?

Get a free copy of the Zacks research report on Aethlon Medical (AEMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with's FREE daily email newsletter.